VRTX · News · 20260814N

End-Market Demand Trends

VERTEX PHARMACEUTICALS INC / MA · 2026-08-14 · Importance 54 · Surprise 40

Vertex’s cystic fibrosis franchise revenue grew 10.6% year over year in the second quarter, indicating continued demand across its core CF treatment market. Revenue also increased 10% sequentially, suggesting sustained near-term momentum rather than a one-time increase. The report characterizes Vertex as continuing to dominate its core therapeutic area while gradually expanding into additional markets.